Search the Newsreel

United Therapeutics CEO Rothblatt sells $4.89m in stock

Martine A. Rothblatt, CEO of United Therapeutics Corp, sold approximately $4.89 million worth of company stock on August 12, 2026, as part of a pre-arranged trading plan, while also exercising options to acquire shares. These sales occurred after UTHR stock saw a 60% return …

United Therapeutics (UTHR) Stock Looks Undervalued Despite Fresh NDA Filings

United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play

United Therapeutics Corp (UTHR) CEO’s trust sells 9,500 shares under 10b5-1 plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), had a family trust execute and sell 9,500 shares. This transaction, conducted on August 12, 2026, was part of a pre-arranged Rule 10b5-1 trading plan. The trust exercised 9,500 stock options at $135.42 …

United Therapeutics Corp (UTHR) CEO trades 9,500 shares after option exercise

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, through a family trust, exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 common shares between $512.94 and $531.29 per share on August 11, 2026. This transaction was conducted under a …

UNITED THERAPEUTICS CORP (UTHR.MX) Analyst insights, Price targets and Recommendations

This article provides analyst insights, price targets, and recommendations for UNITED THERAPEUTICS CORP (UTHR.MX). It lists recent upgrades and downgrades from various financial institutions like RBC Capital, JP Morgan, B of A Securities, and Wells Fargo, detailing their maintained or changed ratings. The stock …

United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript

United Therapeutics (UTHR) CEO trades 9,500 shares under 10b5-1 plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), exercised 9,500 stock options at $135.42 per share and subsequently sold these 9,500 common shares in open-market transactions ranging from $523 to $539 per share on August 10, 2026. This activity was conducted under …

United Therapeutics chairperson & CEO sells $5.05m in stock

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp. (NASDAQ:UTHR), sold 9,500 shares of company stock worth over $5 million on August 7, 2026, after exercising stock options. These transactions were executed under a pre-arranged 10b5-1 trading plan. The article also mentions United …

Baylor College of Medicine strikes multimillion-dollar deal with United Therapeutics for transplant center

Baylor College of Medicine and United Therapeutics have signed a multimillion-dollar agreement to establish the Baylor College of Medicine Center for Xenoliver Transplantation and Immunomodulation. This partnership coincides with United Therapeutics' upcoming opening of its nearly $100 million xenotransplantation facility in Houston. The collaboration …

United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions

United Therapeutics's Q2 Earnings Call: Our Top 5 Analyst Questions United Therapeutics reported second quarter results that modestly exceeded Wall Street's revenue and adjusted EPS expectations, with management highlighting the impact of competitive dynamics in the inhaled prostacyclin market. CEO Dr. Martine Rothblatt emphasized …

Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Martine Rothblatt, CEO of United Therapeutics (NASDAQ:UTHR), sold 9,500 shares of the company's stock for over $5 million, reducing her stake by 2.84%. The sale occurred on August 7th at an average price of $531.38 per share. Despite the sale, United Therapeutics beat earnings …

United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise

United Therapeutics Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares at $135.42 and subsequently sold these shares through a family trust in multiple transactions ranging from $512.50 to $532.3932 per share. These transactions, executed on August 6, 2026, were part …

Stronger EPS, Ralinepag Progress, and Buybacks Might Change The Case For Investing In United Therapeutics (UTHR)

United Therapeutics (UTHR) Stock Still Looks Cheap With Strong Returns Priced In

United Therapeutics Corp (UTHR) CEO sells 9,500 shares under 10b5-1 plan

United Therapeutics Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 shares in multiple transactions on August 5, 2026. These actions were conducted under a pre-arranged 10b5-1 trading plan established on …

How Investors May Respond To United Therapeutics (UTHR) EPS Strength And Ralinepag’s Phase 3 Milestone

In the past week, United Therapeutics reported second-quarter 2026 results showing sales of US$783.3 million, a slight year-on-year decline, while net income rose to US$333 million and diluted EPS increased to US$7.27, alongside continued share repurchases under its US$1.50 billion buyback program. At the …

United Therapeutics' Q2 Tyvaso Miss Reflects Competition; IPF Outreach Set to Expand, Morgan Stanley Says

United Therapeutics' (UTHR) Q2 miss for Tyvaso reflected pressure from rising competition, though th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

Earnings Flash (UTHR) United Therapeutics Corporation Reports Q2 Revenue $783.3M, vs. FactSet Est of $804.6M

United Therapeutics Corporation (UTHR) reported its Q2 revenue at $783.3 million, falling short of FactSet's estimate of $804.6 million. This earnings flash highlights the pharmaceutical company's financial performance for the second quarter, providing key revenue figures against analyst expectations.

Earnings call transcript: United Therapeutics posts Q2 2026 EPS beat, revenue miss

United Therapeutics reported mixed Q2 2026 results, beating EPS estimates with $7.27 per share but missing revenue forecasts at $783.3 million. The stock fell in premarket trading as investors focused on the sales miss and cautious near-term outlook despite pipeline progress in IPF, PAH, …

United Therapeutics (UTHR) Stock Flat As Profit Strength Meets Revenue Doubts

United Therapeutics (UTHR) lifts Q2 EPS, details $2.0B share buyback plan

United Therapeutics reported Q2 2026 financial results, with net income rising to $333.0 million and diluted EPS to $7.27, despite a 2% decrease in total revenues to $783.3 million. The company announced a $2.0 billion share repurchase program, including $1.5 billion in accelerated repurchases, …

United Therapeutics Corp (UTHR) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points United Therapeutics Corp (NASDAQ:UTHR) reported exceptional clinical results from its advanced outcomes study, demonstrating ralinepag's …

BofA cuts United Therapeutics stock price target on Tyvaso sales

BofA Securities lowered its price target for United Therapeutics Corp. (NASDAQ:UTHR) to $559 from $613, while maintaining a Neutral rating, due to weaker-than-expected Tyvaso sales and competitive pressures. The company's second-quarter results included a revenue miss, leading BofA to reduce its fiscal 2026 sales …

United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say

United Therapeutics (UTHR) reported $783.3 million in revenue for the quarter ended June 2026, representing a year-over-year decline of 1.9%. EPS of $7.27 for the same period compares to $6.41 a year ago. The reported revenue represents a surprise of -2.51% over the Zacks …

Is United Therapeutics Corp (UTHR) Overvalued After Q2 Earnings

United Therapeutics (UTHR) Q2 Earnings Surpass Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $7.27 per share, beating the Zacks Consensus Estimate of $6.82 per share. This compares to earnings of $6.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales

UNITED THERAPEUTICS ($UTHR) Releases Q2 2026 Earnings

United Therapeutics Q2 2026 earnings: Lower taxes lift EPS as revenue slips

Press Release: United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

United Therapeutics Corporation announced its financial results for the second quarter of 2026. The report details the company's financial performance, likely including revenue, net income, and earnings per share, for the specified period. This press release provides key insights into the company's operational and …

Net income $607.9M and $1.5B buyback at United Therapeutics (NASDAQ: UTHR)